In this study, we further demonstrate the efficacy of homodimeric minimal FH constructs (HDM-FH, particularly, FH1-5^18-20^R1-2) in the treatment of experimental C3G through the generation of a murine analog and delivery of the human version of the drug via gene therapy. The gene discussed is FLNB; the disease is complement 3 glomerulopathy.